Davids M, van Hell AJ, Visser M, Nijveldt RJ, van Leeuwen PAM, Teerlink T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 302: H1762-H1770, 2012. First published February 24, 2012 doi:10.1152/ajpheart.01205.2011.-Proteolytic activity in whole blood may lead to release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). We investigated the role of the human erythrocyte in storage and generation of ADMA in healthy controls (n ϭ 36) and critically ill patients (n ϭ 38). Both free and total (sum of free and protein-incorporated) ADMA were measured. Upon incubation of intact erythrocytes with extracellular ADMA (0 to 40 mol/l), equilibrium between intra-and extracellular ADMA was reached within 3 h. Compared with controls, patients had significantly higher basal concentrations of ADMA in plasma (0.88 Ϯ 0.75 vs. 0.41 Ϯ 0.07 mol/l) and erythrocytes (1.28 Ϯ 0.55 vs. 0.57 Ϯ 0.14 mol/l). Intracellular and plasma ADMA were significantly correlated in the patient group only (r ϭ 0.834). Upon lysis, followed by incubation at 37°C for 2 h, free ADMA increased sevenfold (to 8.60 Ϯ 3.61 mol/l in patients and 3.90 Ϯ 0.78 mol/l in controls). In lysates of controls, free ADMA increased further to 9.85 Ϯ 1.35 mol/l after 18 h. Total ADMA was 15.43 Ϯ 2.44 mol/l and did not change during incubation. The increase of free ADMA during incubation corresponded to substantial release of ADMA from the erythrocytic protein-incorporated pool (21.9 Ϯ 4.6% at 2 h and 60.8 Ϯ 7.6% at 18 h). ADMA was released from proteins other than hemoglobin, which only occurred after complete lysis and was blocked by combined inhibition of proteasomal and protease activity. Neither intact nor lysed erythrocytes mediated degradation of free ADMA. We conclude that intact erythrocytes play an important role in storage of ADMA, whereas upon erythrocyte lysis large amounts of free ADMA are generated by proteolysis of methylated proteins, which may affect plasma levels in hemolysis-associated diseases. red blood cells; critical illness; proteasome; proteolytic degradation ENDOTHELIUM-DERIVED NITRIC OXIDE (NO), which is synthesized from arginine by nitric oxide synthase (NOS), is an important regulator of vascular homeostasis. Next to being a powerful vasodilator, NO inhibits platelet aggregation, adhesion of leukocytes to the endothelium, and proliferation of smooth muscle cells (36). Inactivation and/or reduced synthesis of NO is seen in conjunction with risk factors for cardiovascular disease and may promote endothelial dysfunction, hypertension, thrombus formation, and atherogenesis (18, 36). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NOS that, by competing with its substrate arginine, impairs NO production (2, 61). Increased plasma levels of ADMA are associated with endothelial dysfunction and atherosclerosis and have been found to predict future cardiovascular events, independent of traditional risk factors (6, 52, 63) .
ENDOTHELIUM-DERIVED NITRIC OXIDE (NO), which is synthesized from arginine by nitric oxide synthase (NOS), is an important regulator of vascular homeostasis. Next to being a powerful vasodilator, NO inhibits platelet aggregation, adhesion of leukocytes to the endothelium, and proliferation of smooth muscle cells (36) . Inactivation and/or reduced synthesis of NO is seen in conjunction with risk factors for cardiovascular disease and may promote endothelial dysfunction, hypertension, thrombus formation, and atherogenesis (18, 36) . Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NOS that, by competing with its substrate arginine, impairs NO production (2, 61) . Increased plasma levels of ADMA are associated with endothelial dysfunction and atherosclerosis and have been found to predict future cardiovascular events, independent of traditional risk factors (6, 52, 63) .
ADMA is continuously formed during intracellular turnover of proteins. Some protein-incorporated arginine residues are posttranslationally methylated by protein arginine methyltransferases to form monomethylarginine and ADMA or symmetric dimethylarginine (SDMA). These modifications serve to expand the functional repertoire of the cellular proteome (3) . During proteolysis of ADMA-containing proteins and peptides, ADMA is released into its free form, which inhibits NOS activity. Most free ADMA is hydrolyzed into citrulline and dimethylamine by the intracellular enzyme dimethylarginine dimethylaminohydrolase (DDAH), which has two isoforms with a wide tissue distribution (46) . ADMA can be exported from the cell to the circulation via cationic amino acid transporters (CAT), which also mediate uptake by other cells or organs, thereby facilitating interorgan transport of ADMA (56) .
Because generation and degradation of ADMA are intracellular events, the circulation is usually considered as a passive transport medium for distribution of free ADMA between cells and tissues. Indeed, it has been shown that albumin and other plasma proteins contain virtually no protein-incorporated ADMA (59, 60) . However, whole blood has been shown to contain large amounts of protein-incorporated ADMA (4, 5, 12, 65) . Billecke et al. (5) demonstrated that human blood is capable of releasing physiologically significant quantities of free ADMA from this protein-incorporated pool via proteolytic pathways. Although this elegant study identified the erythrocyte as a likely source, ADMA concentrations in the erythrocyte cytosol were not measured directly but estimated from data in whole blood and plasma. It also remains to be established whether hemoglobin or other protein constituents of the erythrocyte are the main source of ADMA. Furthermore, DDAH-mediated degradation of free ADMA has been described in rat erythrocytes (4) , but it is not clear whether active DDAH is also present in human erythrocytes. Therefore, the aim of the present study was to further delineate the role of the human erythrocyte in the transport and metabolism of ADMA. We studied the capacity of the intact erythrocyte to exchange free ADMA with its surroundings and examined the relation between intracellular free ADMA and plasma ADMA in healthy individuals and critically ill patients. We also established the size and nature of the protein-incorporated ADMA pool in erythrocytes and investigated the conditions under which free ADMA is released from this pool and the potential mechanisms involved. Finally, we investigated whether degradation of free ADMA occurs in the human erythrocyte.
MATERIALS AND METHODS
Study subjects. Apparently healthy volunteers (n ϭ 36) were recruited amongst laboratory personnel and students, who, after giving written informed consent, kindly donated a blood sample. In addition, blood samples were obtained from critically ill patients (n ϭ 38) of the surgical intensive care unit of the Erasmus Medical Center Rotterdam, The Netherlands. The Institutional Review Board of Erasmus Medical Center approved the protocol, and informed consent was obtained from a first-degree family member. Patients were included if they had clinical evidence of dysfunction of at least two organs. We have previously published on the relation between the plasma concentration of ADMA and mortality in these patients (41) and argued that ADMA may be a causative factor in the development of multiple organ failure (43) . The present study comprises subjects from whom erythrocyte samples had been stored (n ϭ 38, 71.1% male, age range 16 -81). The Sequential Organ Failure Assessment (SOFA) score was calculated (62) , and organ failure was defined as SOFA score Ն3 for any system. The number of failing organ systems (number of patients) was 0 -1 (13), 2-3 (17) , and Ն4 (8). Cardiovascular failure was most common (63.2% of patients), followed by respiratory failure (57.9%), renal failure (31.6%), hepatic failure (23.7%), neurological failure (26.3%), and coagulation failure (21.1%). During their intensive care unit stay, 14 patients (36.8%) died of irreversible multiple organ failure.
Isolation of erythrocytes. Erythrocytes were isolated from EDTA blood by centrifugation (5 min, 1,915 g), separating the erythrocytes from plasma and buffy coat. After 1 ml of plasma was acquired and removal of the remaining plasma and buffy coat, the erythrocytes were washed twice in 0.9% saline (Baxter, Utrecht, The Netherlands). Erythrocytes and plasma samples from individual subjects were stored at Ϫ80°C until further analysis. Additionally, washed erythrocytes from several individuals were pooled and used for experiments with or without prior freezing.
Complete lysis of erythrocytes was accomplished by overnight freezing at Ϫ20°C, followed by thawing and addition of 2 vol of water.
Measurement of ADMA release and uptake by erythrocytes. ADMA release from and ADMA uptake by intact erythrocytes was studied by incubating pooled erythrocytes with various concentrations of ADMA (Sigma, St. Louis, MO). To ϳ200 l of packed erythrocytes (exact amount obtained by weighing), an equal volume of ADMA solution (0 -42 mol/l in saline) was added and incubated at 37°C in a water bath. At timed intervals between 0 and 180 min, tubes were taken from the water bath, rapidly chilled on ice, and centrifuged (10 min at 20,000 g and 4°C). The supernatants were removed, and the erythrocyte pellets were washed once by resuspension in 1 ml of ice-cold saline, followed by centrifugation (10 min at 20,000 g and 4°C). After removal of the supernatants, the erythrocyte pellets were lysed by overnight freezing at Ϫ20°C. After thawing, 400 l water were added and proteins were precipitated by mixing with 600 l ice-cold 1.2 mol/l perchloric acid (PCA; Merck, Darmstadt, Germany), followed by centrifugation (10 min at 20,000 g and 4°C). Free ADMA levels were measured in the medium recovered after incubation, the saline supernatants obtained after washing the erythrocyte pellets, and in the PCA supernatants of the erythrocyte lysates.
Generation of free ADMA induced by erythrocyte lysis. Pooled erythrocytes were lysed by overnight freezing at Ϫ20°C. After thawing, 200 l of the lysed cells (exact amount obtained by weighing) were mixed with 400 l of water and the samples were incubated in a water bath at 37°C. After 1, 2, 3, 4, 6, and 18 h of incubation, tubes were put on ice and proteins were precipitated by mixing with 600 l ice-cold 1.2 mol/l PCA, followed by centrifugation (10 min at 20,000 g and 4°C). Supernatants were stored until determination of free ADMA and other amino acids. At the start and the end of the 18-h incubation period, 50-l aliquots from the incubation mixture were taken for the determination of the total content of ADMA and other amino acids after acid hydrolysis.
To assess the effect of temperature, parallel incubations were performed at 4°C. In addition, control incubations at 37°C with intact erythrocytes from the same pool, diluted with saline instead of water, were performed.
The role of proteolysis on the release of ADMA upon in vitro lysis was studied by the addition of either N␣-tosyl-L-lysine-chloromethylketone (Biomol International, Plymouth Meeting, MA; 0.5 mg/ml in 62.5 mmol/l Na2HPO4, pH 6.0), an inhibitor of the (chymo)trypsinlike activity of the proteasome, or the complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany; 1 tablet/10 ml water), or both. To 200-l aliquots from the lysed erythrocyte pool, 120 l of one or both inhibitors were added and water to make a total volume of 600 l, and the samples were incubated at 37°C for up to 18 h and processed as described above.
ADMA measurements in healthy and critically ill subjects. Plasma concentrations of ADMA and intracellular ADMA in erythrocytes were measured in both healthy subjects and critically ill patients. Erythrocytes were lysed by addition of 2 vol of water after thawing as described above. Free ADMA in the lysates was determined at baseline and after 2-h incubation at 37°C. In healthy subjects, free ADMA was also determined after 18-h incubation, and at 0-, 2-, and 18-h aliquots were taken for determination of total (free and proteinincorporated) ADMA after acid hydrolysis.
Acid hydrolysis. For measurement of total (i.e., the sum of free and protein-incorporated) levels of ADMA and other amino acids, proteins were hydrolyzed by acid hydrolysis. To a 50-l aliquot of the incubation mixture, a 75-l aliquot of a 40 mol/l solution of the internal standard monomethylarginine (MMA) was added. Acid hydrolysis was performed by addition of 875 l 6 mol/l hydrochloric acid (VWR International BDH Prolabo, Amsterdam, The Netherlands), followed by heating at 110°C for 16 h in sealed tubes. After hydrolysis, the samples were cooled and centrifuged (10 min at 20,000 g) and the supernatant was used for analysis of ADMA and other amino acids.
Determination of ADMA. Supernatants obtained after deproteinization with PCA were neutralized by addition of 0.25 mol/l Na2HPO4. Plasma samples and neutralized PCA-supernatants were spiked with the internal standard MMA and then basic amino acids (including the analytes arginine, ADMA, and SDMA and the internal standard MMA) were extracted by solid-phase extraction (SPE) on polymeric cation-exchange columns (57) . After SPE extraction, the samples were dried with nitrogen and derivatized with ortho-phthaldialdehyde reagent containing 3-mercaptopropionic acid, and the analytes were separated by isocratic reversed-phase chromatography (HPLC) on a monolithic column as previously described (14) . Total ADMA (i.e., the sum of free and protein-incorporated ADMA) was determined in acid hydrolysates. A 100-l aliquot of the supernatant obtained after acid hydrolysis was dried under nitrogen at 60°C and dissolved in 100 mmol/l Na2HPO4, pH 8.0, followed by SPE and HPLC analysis as described above. For all analytes, the intra-and interassay coefficients of variation were Ͻ2% and Ͻ4%, respectively.
Determination of amino acids. Concentrations of free amino acids in the PCA-supernatants were measured with reversed-phase HPLC, using automated precolumn derivatization with ortho-phthaldialdehyde reagent containing 3-mercaptopropionic acid and fluorescence detection as previously described (58) . The total amino acid content (i.e., the sum of free and protein-incorporated amino acids) was determined in acid hydrolysates. A 100-l aliquot of the supernatant obtained after acid hydrolysis was dried under nitrogen at 60°C and dissolved in 1 ml 100 mmol/l Na2HPO4, pH 8.0, followed by amino acid analysis as described above. For all amino acids, the intra-and interassay coefficients of variation were Ͻ4% and Ͻ7%, respectively.
Calculation of intracellular concentrations. For calculation of intracellular concentrations of ADMA and other amino acids in erythrocytes, the water content was assumed to be 66% of erythrocyte weight as described by Flügel-Link et al. (17) .
Statistical analyses. Data are presented as means Ϯ SD, unless otherwise indicated. The paired-Student's t-test was used for comparison of ADMA levels between plasma and erythrocytes of individual subjects and for comparison between incubation periods. ADMA levels in critically ill and healthy subjects were compared using the independent-samples t-test. Univariate relations between variables were investigated using Pearson's correlation analysis. A two-tailed P value Ͻ 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL).
RESULTS
Release and uptake of ADMA by intact erythrocytes. The capacity of erythrocytes to release and take up ADMA was studied by incubating a pool of intact erythrocytes for 3 h at 37°C with saline, containing increasing concentrations of ADMA. Incubation with medium devoid of ADMA resulted in a slow release of ADMA from the erythrocytes to the extracellular medium (Fig. 1A) . During incubation, the intra-and extracellular ADMA concentrations gradually converged, but full equilibrium was not reached during the 3-h incubation period. When the initial concentration of ADMA in the extracellular medium exceeded the intracellular ADMA concentration, net uptake of ADMA by the erythrocytes occurred (Fig. 1,  B-E ). At all concentrations tested, rapid inflow of ADMA resulted in ADMA concentrations being higher in the cell than in the medium at 15 min, as reflected by an intracellular-tomedium concentration ratio exceeding 1 (Fig. 1F) . After this initial overshoot, intra-and extracellular ADMA concentrations converged and were almost equal at 3 h, irrespective of the initial extracellular ADMA concentration. At the end of the incubation period, the calculated recovery of ADMA, i.e., the Fig. 1 . Asymmetric dimethylarginine (ADMA) release and uptake by intact erythrocytes. A pool of erythrocytes was incubated at 37°C with an equal volume of saline (A) or saline containing increasing concentrations of ADMA (B-F). Afterwards, the erythrocytes were separated from the medium by centrifugation and intracellular and medium free ADMA concentrations were measured. Intraerythrocytic-to-medium concentration ratios of ADMA were calculated (F). Values are means Ϯ SD; n ϭ 3. sum of ADMA in the intracellular and extracellular compartments and the saline wash, expressed as a fraction of the total amount of ADMA at the start of the incubation, ranged between 99.3 and 103.0%.
Generation of ADMA in erythrocyte lysates. Experiments on pooled erythrocytes were performed to gain more insight in the origin and kinetics of lysis-induced ADMA generation. Lysis of erythrocytes followed by incubation at 37°C resulted in a rapid increase of the ADMA concentration in the lysate (Fig. 2) . The initial ADMA concentration of 0.53 Ϯ 0.01 mol/l more than doubled during the first hour of incubation and further rose to 4.94 Ϯ 0.07 mol/l at 18 h, without reaching a clear plateau. The increase of ADMA during the 18-h incubation period (4.41 Ϯ 0.07 mol/l) was much smaller when incubation was performed at 4°C (0.61 Ϯ 0.04 mol/l) and almost negligible in intact erythrocytes incubated at 37°C (0.27 Ϯ 0.12 mol/l).
ADMA generation during incubation of lysed erythrocytes at 37°C was reduced by 12.2% when activity of the proteasome was inhibited and by 56.9% when activity of proteases was inhibited. Combined inhibition of proteasomal and protease activity reduced ADMA generation by 87.4%, which was equally effective as lowering the incubation temperature from 37°C to 4°C (Fig. 2) .
These results suggest that proteolysis of methylated proteins, rather than de novo ADMA synthesis, is the cause of the generation of free ADMA in erythrocyte lysates. To further investigate this issue, we assessed whether the increase in free ADMA was accompanied by changes in total ADMA, i.e., the sum of free and protein-incorporated ADMA. In acid hydrolysates of the erythrocyte lysates, we observed no significant difference between total ADMA concentrations measured in triplicate at baseline and after 18-h incubation at 37°C (15.95 Ϯ 0.56 vs. 16.31 Ϯ 0.51 mol/l, respectively; P ϭ 0.45). This means that the 4.41 Ϯ 0.07 mol/l increase of free ADMA after 18-h incubation is equivalent to conversion of 27.4 Ϯ 1.0% of the protein-incorporated ADMA pool into free ADMA. Similar calculations were performed for SDMA. The concentration of total SDMA was approximately eightfold lower compared with ADMA but, like ADMA, did not change significantly during incubation (1.92 Ϯ 0.20 mol/l at baseline vs. 2.21 Ϯ 0.17 mol/l at t ϭ 18 h; P ϭ 0.14). The increase of free SDMA during the incubation was 0.23 Ϯ 0.01 mol/l, corresponding to release of 10.9 Ϯ 1.3% of protein-incorporated SDMA.
Because it seemed highly unlikely that under these conditions Ͼ10% of the erythrocyte proteome is degraded to free amino acids, we also investigated the release of common amino acids from proteins. The total amount of amino acids in the erythrocyte lysate, measured after acid hydrolysis, was 4.52 Ϯ 0.23 mol/l (n ϭ 3). The relative amount of the individual amino acids closely resembled the amino acid composition of human hemoglobin (␣ 2 ␤ 2 ) calculated from sequence data (Fig. 3 ), in accord with the fact that hemoglobin almost fully accounts for the protein content of the erythrocyte. This was also reflected by the low content (0.34 Ϯ 0.02%) of isoleucine, the only common amino acid that is not present in human hemoglobin and therefore originates from other proteins. The total amount of free amino acids in the erythrocyte lysate was 328 Ϯ 8 mol/l at baseline and increased to 982 Ϯ 7 mol/l after an 18-h incubation. The increase of 654 Ϯ 10 mol/l is equivalent to release of 0.015 Ϯ 0.001% of amino acids from the proteinincorporated pool. The release of individual amino acids present in hemoglobin was also very low, varying from almost undetectable to 0.033 Ϯ 0.002% for alanine (Fig. 4) . Release of isoleucine, not present in hemoglobin, was slightly higher Fig. 3 . Comparison of the amino acid composition of erythrocytes and hemoglobin. After acid hydrolysis of an erythrocyte pool, amino acids were measured by HPLC and expressed as percentage of the total amount of amino acids recovered (grey bars). Values are means Ϯ SD; n ϭ 3. Relative amino acid composition of human hemoglobin (␣2␤2) was calculated from sequence data (black bars). Amino acids that cannot be measured with the HPLC method (proline and cysteine) or that are degraded during acid hydrolysis (tryptophan and methionine) were excluded from the calculations. Because acid hydrolysis causes deamidation of asparagine and glutamine, the sum of aspartic acid and asparagine (Asx) and of glutamine and glutamic acid (Glx) is reported. (0.063 Ϯ 0.004%) but still Ͼ100-fold lower than the release of ADMA (27.4 Ϯ 1.0%) and SDMA (10.9 Ϯ 1.3%).
To gauge potential activity of DDAH, which degrades ADMA into citrulline and dimethylamine, citrulline was also measured. Citrulline, measured in triplicate, did not change significantly during incubation of the erythrocyte lysates at 37°C (3.36 Ϯ 0.14 mol/l at baseline vs. 3.52 Ϯ 0.17 mol/l at t ϭ 18 h; P ϭ 0.26), indicating absence of DDAH activity.
ADMA in erythrocytes and plasma from healthy and critically ill subjects. As illustrated in Fig. 5 , the concentration of ADMA in plasma was significantly higher in critically ill patients than in healthy subjects (0.88 Ϯ 0.75 vs. 0.41 Ϯ 0.07 mol/l; P Ͻ 0.001). This was also the case for the intracellular ADMA concentration in erythrocytes (1.28 Ϯ 0.55 vs. 0.57 Ϯ 0.14 mol/l; P Ͻ 0.001). In both groups, the intracellular ADMA concentration was significantly higher than the plasma ADMA concentration (P Ͻ 0.0001; Fig. 5 ), but this concentration gradient was more pronounced in the patient group, as reflected by a higher intracellular-to-plasma concentration ratio (1.78 Ϯ 0.59 in patients vs. 1.43 Ϯ 0.39 in controls; P ϭ 0.003).
Correlation analysis revealed that intracellular and plasma concentrations of ADMA were significantly related in the patient group (r ϭ 0.834; P Ͻ 0.0001; Fig. 6B ) but not in healthy subjects (r ϭ 0.072; P ϭ 0.68; Fig. 6A ). This might be partly caused by the wider range of ADMA concentrations in the patient group. However, when the analysis in critically ill patients was restricted to subjects with plasma ADMA concentrations in the range of healthy subjects, i.e., Ͻ0.6 mol/l (n ϭ 16), the association between intracellular and plasma ADMA was attenuated but remained significant (r ϭ 0.529; P ϭ 0.035).
Generation of ADMA in erythrocyte lysates of healthy and critical ill subjects. To determine if generation of ADMA in erythrocyte lysates occurs to the same extent in critically ill patients and in healthy subjects, erythrocyte lysates were prepared and incubated at 37°C. In all subjects, the ADMA concentration increased significantly during incubation for 2 h (from 0.57 Ϯ 0.14 to 3.90 Ϯ 0.78 mol/l in healthy subjects and from 1.28 Ϯ 0.55 to 8.60 Ϯ 3.61 mol/l in patients; both P Ͻ 0.0001; Fig. 7 ). Although the absolute increase of ADMA was much higher in the patient group, the relative increase did Fig. 6 . Scatterplots of the relation between plasma ADMA and intracellular free ADMA in erythrocytes of healthy subjects (A) and critically ill patients (B). Strengths of the associations are indicated by Pearson correlation coefficients. Fig. 4 . Release of free amino acids from protein after erythrocyte lysis. A pool of erythrocytes was lysed and incubated at 37°C. At t ϭ 0 h and t ϭ 18 h a sample was taken for measurement of ADMA, symmetric dimethylarginine (SDMA), and other free amino acids. Increase in the concentration of free amino acids during incubation is expressed as percentage of the total amount (sum of free and protein-incorporated) of amino acids at t ϭ 0 measured after acid hydrolysis. Values are means Ϯ SD; n ϭ 3. Amino acids that cannot be measured with the HPLC method (proline and cysteine) or that are degraded during acid hydrolysis (tryptophan and methionine) were excluded from the calculations. Because acid hydrolysis causes deamidation of asparagine and glutamine, the sum of aspartic acid and asparagine (Asx) and of glutamine and glutamic acid (Glx) is reported. Fig. 5 . Concentration of free ADMA in plasma and erythrocytes of healthy subjects (n ϭ 36) and critically ill patients (n ϭ 38). Values are means Ϯ SE. *P Ͻ 0.001 critically ill vs. healthy subjects.
† P Ͻ 0.0001 erythrocytes vs. plasma.
not significantly differ between both groups (7.0 Ϯ 1.6-fold in healthy subjects vs. 6.9 Ϯ 2.2-fold in patients; P ϭ 0.69). In healthy subjects, incubation was continued until 18 h, and by that time the free ADMA concentration had further risen to 9.85 Ϯ 1.35 mol/l (P Ͻ 0.0001 vs. t ϭ 2 h), almost equal to the concentration that was reached in the critically ill patients already after a 2-h incubation.
Aliquots of the incubation mixture taken at baseline and 18 h were hydrolyzed for determination of total ADMA, i.e., the sum of free and protein-incorporated ADMA. Total ADMA did not significantly change during the incubation (15.43 Ϯ 2.44 mol/l at baseline vs. 14.92 Ϯ 2.35 mol/l at t ϭ 18 h; P ϭ 0.17). The increase of free ADMA after 2 and 18 h of incubation (compared to baseline 3.33 Ϯ 0.74 and 9.27 Ϯ 1.31 mol/l, respectively) corresponded to conversion of a substantial fraction of the protein-incorporated ADMA pool into free ADMA (21.9 Ϯ 4.6 and 60.8 Ϯ 7.6%, respectively).
DISCUSSION
In this study, we investigated the role of erythrocytes in the storage and generation of the endogenous NOS inhibitor ADMA. Our results indicate that there is fast bidirectional traffic of ADMA across the plasma membrane of the intact erythrocyte, leading to a rapid equilibrium between intra-and extracellular ADMA. Upon lysis of erythrocytes, proteolytic activity leads to a substantial release of free ADMA from methylated proteins but without appreciable contribution from hemoglobin. No DDAH-mediated degradation of free ADMA by erythrocytes was observed. Taken together, the results of this study indicate that the erythrocyte can serve both as a reservoir and a source of free ADMA.
ADMA release and uptake by the human erythrocyte. The transport of cationic amino acids, including arginine and ADMA, across the erythrocyte membrane is facilitated by system y ϩ , and by system y ϩ L, which next to cationic amino acids also recognizes large neutral amino acids (11, 15) . A family of CAT transporter proteins is responsible for the activity of system y ϩ , whereas y ϩ LAT transporters mediate the activity of the y ϩ L system (8) . Notably, CAT transporters operate as a facilitated diffusion system driven by the membrane potential. Virtually all eukaryotic cells, including erythrocytes (23), maintain a nonzero transmembrane potential, with a negative voltage in the cell interior compared with the cell exterior, thereby stimulating CAT-mediated uptake of positively charged amino acids. For arginine, it has been demonstrated that its distribution ratio, in accordance with the Nernst equation, accurately reflects the membrane potential (10) . Under physiological conditions, the membrane potential of the erythrocyte in blood, as calculated from the Goldman-Hodgkin-Katz equation, is Ϫ14.3 mV (31). Application of the Nernst equation indicates that, at this potential, CAT-mediated exchange of singly charged positive amino acids will equilibrate at an intracellular concentration that is 1.71-fold higher than the extracellular concentration. Notably, this theoretical distribution ratio is close to the values we measured for ADMA in blood samples (intracellular-to-plasma ratio of 1.43 Ϯ 0.39 in healthy subjects and 1.78 Ϯ 0.59 in critically ill patients).
Relation between ADMA in erythrocytes and plasma in health and disease. Previous studies (1, 16) have demonstrated that both plasma and erythrocytes contribute to the interorgan transport of amino acids. Consequently, whole blood cannot be viewed as a single compartment, but the contributions of the plasma and the erythrocyte compartments should be considered separately, especially for amino acids that do not equilibrate well between plasma and blood cells (21) . We studied the relation between ADMA in plasma and erythrocytes in apparently healthy individuals and critically ill patients. In line with the results of the in vitro experiments, in almost all subjects the intracellular concentration of ADMA exceeded its concentration in plasma. Remarkably, a significant association between intracellular and plasma concentrations of ADMA was only observed in patients and not in controls. The poor correlation in healthy individuals is in line with results of a study with stable isotope labeled amino acids in rats, showing a poor equilibration of arginine between plasma and erythrocytes (21) . Possibly, the closer relation between intra-and extracellular ADMA in critical illness is caused by upregulation of CAT in the plasma membrane. Upregulation of CAT in erythrocytes has indeed been demonstrated in patients with chronic renal or heart failure (9, 22, 34, 35) and also in pregnant women with preeclampsia (13) . Next to changed expression levels of CAT in the erythrocyte membrane, also uptake of ADMA from the plasma by tissues may affect the plasma-erythrocyte equilibrium. Kidneys and liver have a high DDAH activity and both organs contribute to clearance of ADMA from the circulation (40, 42, 44, 48, 53, 64) . Rapid clearance of ADMA from the circulation has been demonstrated by Kielstein et al. (28) by infusion of ADMA into healthy subjects. In these experiments, a mean plasma half-life of 24 Ϯ 7 min was calculated from the plasma ADMA decay curves. Clearance-induced attenuation of the correlation between ADMA in plasma and erythrocytes will likely be substantial in healthy individuals but may be less pronounced in critically ill patients, in whom DDAH activity and thus clearance is impaired.
Generation of ADMA in erythrocyte lysates. The rapid increase of free ADMA during incubation of erythrocyte lysates at 37°C was due to enzymatic degradation of methylated proteins, because the process was temperature dependent and almost completely blocked in the presence of inhibitors of proteases and the proteasome. During maturation, erythrocytes undergo a series of differentiations, including loss of nucleus, ribosomes, and mitochondria. Consequently, all capacity for cell division and protein synthesis is lost. Therefore, mature erythrocytes would be expected to have minimal turnover of proteins, since replacement of degraded proteins by de novo synthesis is not possible. However, erythrocytes are capable of degrading (oxidatively) damaged proteins by the catalytic action of the 20S proteasome (39, 45, 47) . Lysis of erythrocytes, by inducing oxidative damage or conformational changes of intracellular proteins, probably triggers proteasomal degradation. The proteasome generates peptides of seven to nine amino acids long, which subsequently can be degraded into single amino acids by proteases (54, 66) . Therefore, release of free ADMA from methylated proteins requires the combined action of the 20S proteasome and a number of different proteases, which is consistent with our observation that ADMA generation was most effectively blocked by combined inhibition of proteasomal and protease activities.
In erythrocyte lysates, Ͼ25% of protein-incorporated ADMA was released as free ADMA after 18-h incubation. This is in strong contrast with common amino acids that are present in hemoglobin, of which Ͻ0.04% was released during incubation (Fig. 4) . The low degradation rate of hemoglobin may reflect stability of its compact quaternary structure. Isoleucine, that is not present in human hemoglobin, was released at a slightly higher rate (0.06%), indicating that proteins other than hemoglobin may be more sensitive towards proteasomal degradation. However, the rate of release of ADMA and SDMA was Ͼ100-fold higher, indicating that proteins methylated at arginine residues may be degraded at an extremely high rate. We (55) have previously also observed very high rates of release of ADMA and SDMA from methylated proteins during incubation of rat kidney homogenates. In contrast to other posttranslational modifications that are reversible, such as phosphorylation, arginine methylation is virtually irreversible. This implies that if arginine methylation is considered as a switch that turns on a particular function of a protein, degradation of the entire protein may be the only way to switch off that function. A high intrinsic sensitivity of argininemethylated proteins towards proteasomal degradation may thus enhance flexibility of arginine methylation as a tool to modulate protein function.
Several other investigators (4, 5, 12, 65) have previously provided evidence for release of ADMA from whole blood or erythrocytes. Hemoglobin is by far the most abundant protein constituent of the erythrocyte, but there is some controversy whether or not it is a likely source of ADMA (12, 60) . Our data clearly demonstrate that hemoglobin is not the main source of free ADMA released upon erythrocyte lysis. However, proteomic analysis has revealed the existence of Ͼ750 proteins within the human erythrocyte (20, 47) , and a recent study (39) identified 28 proteins whose content was affected by proteasomal activity in intact erythrocytes. In our opinion, the source of ADMA should be sought among one of these nonhemoglobin members of the complex erythrocyte proteome.
Absence of DDAH activity in erythrocytes. Our results strongly suggest the absence of active DDAH in the erythrocyte. First, in the experiments in which we examined exchange of free ADMA across the erythrocyte membrane, the recovery of ADMA at the end of the incubation period was essentially complete at all ADMA concentrations tested. Second, although a substantial fraction of protein-incorporated ADMA was released into its free form during incubation of erythrocyte lysates, the total amount of ADMA remained constant. This is in line with the results obtained by Billecke et al. (5) , who also observed an increase of free ADMA without a change of total ADMA during incubation of whole blood lysates. Finally, DDAH-mediated degradation of ADMA would lead to production of citrulline, but the concentration of citrulline in the erythrocyte lysates did not increase during incubation. Taken together, our results do not confirm the presence of active DDAH in human erythrocytes as previously reported by Kang et al. (24) . On a parallel note, Böhmer et al. (7), using a sophisticated gas chromatography-mass spectrometry assay, convincingly demonstrated lack of NOS activity in erythrocytes. The absence of active DDAH and NOS enzymes indicates that intraerythrocytic ADMA probably has no functional role in the regulation of NO production by the erythrocyte.
Study limitations. To study uptake and release of ADMA by intact erythrocytes, washed erythrocytes were incubated with ADMA in isotonic saline solutions. In whole blood, the rate of exchange of ADMA across the plasma membrane will be different, because other cationic amino acids, such as SDMA, arginine, lysine, and ornithine, compete with ADMA for CATmediated transport. In addition, the rate of transport may be enhanced by the presence of cationic amino acids on the opposite side of the membrane, a phenomenon known as transstimulation (11, 15) . Therefore, the results of these experiments merely reveal the capacity of erythrocytes for rapid exchange of ADMA across their membrane but should not be regarded to quantitatively model the in vivo process.
We deliberately chose to investigate healthy volunteers and critically ill patients as representatives of the extremes of the (patho)physiological spectrum. Our data clearly show differences between these groups with respect to cytosolic ADMA in intact erythrocytes and generation of free ADMA upon lysis. However, because both groups were not matched in any way, we cannot draw any definitive conclusions on the potential clinical significance of these differences. This would require further experiments in a well-controlled clinical study.
Potential clinical consequences. Our data show that the erythrocyte is an important player in the generation, storage, and transport of ADMA. Intact erythrocytes can take up and store ADMA from their surroundings and are also able to release ADMA when extracellular concentrations are lower. In healthy subjects, the concentration of ADMA in the erythrocyte cytosol is higher than in plasma and in critically ill patients this contrast is even more pronounced. This implies a role for the erythrocyte in the temporary storage and interorgan transport of free ADMA and indicates that this faculty of the erythrocyte may be most conspicuous in critical illness.
Lysis of erythrocytes results in generation of substantial amounts of free ADMA, released from methylated proteins by rapid proteasomal and proteolytic degradation. In critically ill patients, this process occurs in vitro at a higher rate than in healthy individuals (Fig. 7) , consistent with previous studies (30, 49) showing increased levels of the 20S proteasome in the circulation and increased proteasomal activity in skeletal muscle of critically ill patients. Upon intravascular lysis of erythrocytes, the cytosolic ADMA that was originally present in the erythrocyte before lysis, as well as the free ADMA generated during lysis-associated proteolysis, is spilled into the plasma compartment from where it may be taken up by other cells, including intact erythrocytes. Considering the large reservoir of protein-incorporated ADMA in erythrocytes, lysis of even a small fraction of erythrocytes may therefore lead to a clinically relevant rise of ADMA concentrations, not only in plasma and erythrocytes, but also in tissues that are in intimate contact with the blood compartment, like the vascular endothelium. ADMA generation by hemolysis may contribute to the high plasma ADMA levels observed in patients with sickle cell disease (25, 32, 50) and HELLP syndrome (51) and possibly also in other hemolysis-associated diseases. Release of ADMA from lysed erythrocytes may also occur as a consequence of ex vivo shear stress during hemodialysis of patients with end-stage renal failure. This might explain the observations that the decrease of plasma ADMA after hemodialysis is less than might be expected from its molecular weight (26, 29) and that plasma ADMA levels appear to be lower in patients treated with peritoneal dialysis compared with patients on hemodialysis (27, 37) .
The dual role played by erythrocytes and hemoglobin in the metabolism of NO is increasingly recognized. On the one hand, the erythrocyte may limit the bioavailability of NO, either by reducing its production through arginase-catalyzed consumption of arginine (38) or by hemoglobin-mediated scavenging of NO (19) . On the other hand, under hypoxic conditions, the erythrocyte may contribute to NO production, via hemoglobincatalyzed reduction of nitrite (19, 33) . Storage and generation of the NOS inhibitor ADMA further add to the portfolio of the erythrocyte with respect to regulation of NO metabolism.
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